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The first structure of a P450 to an atomic resolution of
1.06 Å has been solved for CYP121 from Mycobacterium
tuberculosis. A comparison with P450 EryF (CYP107A1)
reveals a remarkable overall similarity in fold with major
differences residing in active site structural elements.
The high resolution obtained allows visualization of sev-
eral unusual aspects. The heme cofactor is bound in two
distinct conformations while being notably kinked in one
pyrrole group due to close interaction with the proline
residue (Pro346) immediately following the heme iron-li-
gating cysteine (Cys345). The active site is remarkably
rigid in comparison with the remainder of the structure,
notwithstanding the large cavity volume of 1350 Å3. The
region immediately surrounding the distal water ligand is
remarkable in several aspects. Unlike other bacterial
P450s, the I helix shows no deformation, similar to mam-
malian CYP2C5. In addition, the positively charged Arg386
is located immediately above the heme plane, dominating
the local structure. Putative proton relay pathways from
protein surface to heme (converging at Ser279) are identi-
fied. Most interestingly, the electron density indicates
weak binding of a dioxygen molecule to the P450. This
structure provides a basis for rational design of putative
antimycobacterial agents.
The cytochromes P450 (P450s)1 are a superfamily of heme-
containing mono-oxygenases (1). They are famed for their roles
in drug metabolism/detoxification and steroid synthesis in
mammals (e.g. Refs. 2 and 3) but are also found in virtually all
other life forms. The vast majority of P450s bind and cleave
molecular oxygen in a two-step reaction involving delivery of
two electrons from a redox partner. In eukaryotic P450s, this is
typically the diflavin enzyme NADPH cytochrome P450 reduc-
tase (4). However, in prokaryotes the reducing equivalents are
usually supplied via two enzymes: NAD(P)H flavodoxin/ferre-
doxin reductase and either a ferredoxin or a flavodoxin medi-
ator of electrons to the P450 (5, 6). Many bacterial P450s are of
particular biotechnological and environmental relevance, given
their role in degradation of recalcitrant organic molecules for
use as energy sources (e.g. Refs. 7 and 8). Bacterial P450s have
also proven to be experimentally tractable systems for elucida-
tion of P450 structure and mechanism, due largely to the fact
that they are soluble enzymes, as opposed to their eukaryotic
membrane-associated counterparts (5). A breakthrough was
made recently with the atomic structure of the first mammalian
P450 (a form of P450 2C5). In this case, extensive protein engi-
neering was required to remove the N-terminal membrane an-
chor peptide, to promote release from the cellular membrane and
to prevent aggregation of the resultant solubilized P450 (9).
Whereas the genome sequence of E. coli is devoid of P450-
encoding genes (10), the genomes of the industrially important
bacterium Streptomyces coelicolor and the pathogen Mycobac-
terium tuberculosis (Mtb) indicate that there are 18 and 20
P450s encoded, respectively (11, 12). The genome sequence of
Mtb revealed several interesting features, most notably the
preponderance of genes involved in lipid metabolism; 250
enzymes involved in lipid metabolism have been identified in
Mtb (cf. 50 for the similarly sized Escherichia coli genome).
The importance of lipid metabolism in Mtb may explain the
high P450 content, since typical cellular functions for P450s in
eukaryotes and other bacteria are as mono-oxygenases for li-
pophilic fatty acids, polyketides, steroids, and xenobiotics (e.g.
see Ref. 2). Sterols are rare in bacteria, but the P450 product of
the Mtb Rv0764c gene (CYP51) is highly related to eukaryotic
sterol demethylases and has been shown to catalyze demethy-
lation of plant and eukaryotic sterols (13). The crystal structure
of the Mtb CYP51 was solved in complex with the azole anti-
fungal drug fluconazole (14). This structure is of biotechnolog-
ical importance, given the importance of the eukaryotic
CYP51s in physiology and also in view of the fact that the yeast
and fungal CYP51 enzymes (lanosterol demethylases) are val-
idated targets for the azole antifungal class of drugs of which
fluconazole is a member (15). In recent studies, the potency of
these drugs as antibiotics against growth of Mtb’s relative
Mycobacterium smegmatis and the related actinomycete
S. coelicolor has been shown (16).
The biochemical functions of the remaining P450 enzymes in
Mtb are not immediately obvious. This is primarily because of
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limited similarity to other members of the P450 superfamily
with known catalytic properties. Most show highest similarity
to other P450 enzymes in Mtb, perhaps suggesting co-evolution
as oxygenases of related, complex lipids in the bacterium (17).
We decided to focus efforts on the product of gene Rv2276, a
P450 enzyme classified as CYP121 (1). This P450 shows amino
acid sequence similarity to a number of polyketide mono-oxy-
genase P450s, including the structurally characterized P450
EryF (CYP107A1) from Saccharopolyspora erythraea (18), sug-
gesting a potential role in polyketide metabolism in Mtb. In
addition, the known high affinity of P450 EryF for the azole
antifungal class of drugs suggests that CYP121 could be a
potential drug target in the pathogen, particularly since the
role of CYP51, its validity as a drug target, and whether sterol
metabolism is really a feature of the pathogen remain to be
established. Indeed, the fact that a CYP51 strain of S. coeli-
color is nonlethal (16, 19) and that the strain exhibits no
significant alteration in sensitivity to azole antifungal drugs
(16) confirms that CYP51 is not the target in this actinomycete.
Our initial expression and biophysical studies have estab-
lished that the Mtb P450 CYP121 has properties typical for
members of this class (20). Whereas the physiological role
remains unclear, the enzyme binds bulky azole antifungal
drugs with high affinity, and the binding constants for these
drugs are perturbed by the presence of erythromycin and other
large polyketides, suggesting that CYP121 may metabolizes
polyketides or bulky polycyclics in vivo. However, what is most
remarkable is that in comparison with Mtb CYP51, the binding
of a variety of azole antifungal drugs to Mtb CYP121 is tighter
and that the order of their Kd values correlates well with the
minimal inhibitory concentration values for these drugs for
M. smegmatis and S. coelicolor (16). Since the drugs retain
their high potency against a S. coelicolor CYP51 knockout
strain, other P450 enzyme(s) must be the true targets in this
bacterium; thus, the fact that potency of azole drugs versus
mycobacteria correlates with CYP121 Kd values must make
this a prime drug target candidate (20). We have previously
reported crystallization of CYP121 (21), and in this paper we
report the crystal structure of CYP121 to 1.06 Å. This unprec-
edented level of resolution for a P450 system allows, for the
first time, a truly atomic description of the oxygen scission site.
EXPERIMENTAL PROCEDURES
Expression and Purification of CYP121—The Rv2276 gene encoding
CYP121 was cloned by PCR from a Mtb chromosomal DNA library
(cosmid MTCY339, obtained from Prof. Stewart Cole at the Institut
Pasteur, Paris, France) and cloned into expression plasmid pET11a to
produce clone PKM2b, as described previously (20). The CYP121 pro-
tein was produced in E. coli strain HMS174 (DE3) with growth of the
culture after isopropyl-1-thio--D-galactopyranoside induction per-
formed at low temperature (18 °C) to promote production of soluble
enzyme. The cells were broken using a French press and sonication, and
CYP121 was purified to homogeneity by ammonium sulfate fraction-
ation (30–70% fraction retained), followed by successive column chro-
matography steps on phenyl-Sepharose, Q-Sepharose, and hydroxyap-
atite resins, as described (20).
Crystallization and Structural Elucidation of CYP121—CYP121 crys-
tals belonging to space group P6522 (unit cell dimensions a  77.81 Å, c 
263.82 Å) were obtained as described previously (21). A complete native
data set up to 1.06 Å could be measured on a single flash-cooled crystal on
ID14–4 at the European Synchrotron Radiation Facility. Different sec-
tions of the crystal were exposed to avoid excessive radiation damage due
to the intense beam. Whereas these crystals clearly diffract further, both
the long cell axis of 263 Å and the rapid decay of diffraction quality
hampered the collection of higher resolution reflections. Data were pro-
cessed and scaled with the HKL package programs DENZO and SCALE-
PACK (22). Despite the availability of several P450 structures, the crystal
structure could not be solved using molecular replacement and was solved
using a Multiple Isomorphous Replacement with Anomalous Scattering
(MIRAS) approach instead. Data were collected on station 14-1 at Syn-
chrotron Radiation Source for two independent heavy metal derivatives.
Initial heavy atom sites were found using the program RSPS (23) and
used for detection of minor sites by difference Fourier analysis. Heavy
atom sites were refined using the program MLPHARE (24), and the weak
anomalous signal of the iron was included in the final phase calculations.
Data collection and phasing statistics are given in Table I. The program
ARP-WARP (25) was used to build an initial model in the solvent flat-
tened maps. This initial model was manually adjusted using TURBO-
FRODO (26) and refined using REFMAC5 (27). The structure of the
uncomplexed enzyme was refined with anisotropic B-factors for all atoms
including a riding hydrogen atom model. With successive rounds of re-
finement and model building, the entire CYP121 sequence was fitted to
the electron density map with the exception of the N-terminal three
residues. Multiple conformations were observed for 33 of the 395 residues
defined. The final R-factor was 0.132 (R-free  0.153) for the model
consisting of the protein, 800 water molecules, and 3 sulfates per asym-
metric unit. The enzyme was complexed with hydrophilic compounds by
soaking in the mother liquor (2.3 M ammonium sulfate, pH 6.5) supple-
mented with a large excess of the ligand. In order to obtain data on
complexes with hydrophobic compounds, the crystals were placed in 30%
polyethylene glycol 8000, 0.2 M ammonium sulfate, pH 6.5, supplemented
with the compound of interest. Only the hydrophilic iodopyrazole proved
to bind in the active site, and data were collected for complexed crystals to
1.8 Å. Final refinement statistics for the two crystal structures are given
in Table II.
RESULTS AND DISCUSSION
General Structural Features—Globally, the CYP121 struc-
ture resembles a triagonal prism, as observed for all other P450
structures to date. As with other P450s, there are two distinct
structural “domains,” with the heme sandwiched between a
smaller  sheet-rich module and a larger helix-rich domain
(Fig. 1). The P450s have relatively few definitive amino acid
motifs, and evolutionarily distinct P450s may exhibit as little
as 15% amino acid identity. However, the cysteine ligand to the
heme iron and the region immediately surrounding this amino
acid (the “heme-binding” motif) at the C-terminal section of the
P450 are strongly conserved (Fig. 2).
Overall Enzyme Fold—Despite the elucidation of several
P450 crystal structures, new cytochrome P450 models often
reveal distinct structural features that are unpredictable from
primary sequence alignments. Given the relative low homology
TABLE I
Data collection and phasing statistics for CYP121
Data set Native Iodopyrazole PtCN K2PtCl4 Hg(NO3)2
Source ESRF-ID14.4 DESY-X11 SRS 14.1 Rotating anode Rotating anode
Resolution (Å) 10–1.06 20–1.8 20–2.5 20–4.3 20–2.8
Unique observations 185,472 44,862 16,817 3544 11,923
Completeness (%) 88.5 95.9 97.2 98.1 95.5
Rmerge (%)
a 9.2 7.2 5.1 8.4 7.8
I/I 6.5 8.1 28.9 9.2 12.7
Temperature (K) 107 107 107 107 107
Heavy atom sites 2 3 3 1
FOM 2.0–2.3 Å 0.42
a Rmerge(I)  hiIh,i  Ih/hiIh,i where I is the observed intensity. I is the average intensity of multiple observations of symmetry-related
reflections.
Atomic Structure of Mtb CYP1215142
(25.3% identity over 396 amino acids) with P450 EryF
(CYP107A1; a macrolide monooxygenase) and the unsuccessful
molecular replacement, the high three-dimensional similarity
of the substrate-free CYP121 with that of substrate/inhibitor-
bound CYP107A1 comes as a surprise (28, 29). Notwithstand-
ing this high similarity in fold (Z score 42.3, root mean square
deviation 2.6 Å for 379 C- atoms), several distinct features can
be observed in CYP121 for polypeptide stretches lining the
active site cavity.
Upon comparison of CYP121 with CYP107A1 from N to C
terminus, the first region that is drastically different is that
immediately following the conserved B helix (Fig. 3). Starting
at residue Met62, the polypeptide chain proceeds first with a 310
helix and then with an extended loop forming the dome of the
active site relative to the heme plane. This loop proceeds into a
second 310 helix that is immediately followed by helices B and
C. The corresponding polypeptide region in CYP107A1 is lon-
ger and bears little or no resemblance, having no regular 310
helical structure, whereas helix B is separated from C by
several residues. The C helix in CYP121 is immediately adja-
cent to helix B and makes a different angle with other con-
served structural elements. It is separated from the short D
helix by a flexible region that precedes Glu110. From this posi-
tion onward, both polypeptide chains again assume very simi-
lar positions. After helix D and E, the helices F and G are
slightly reoriented with respect to the remainder of the struc-
ture, and the FG loop that forms a part of the active site dome
is bent inward with respect to the CYP107A1 structure.
Whereas the CYP121 helix H still occupies a distinct confor-
mation, as does the beginning of helix I, the polypeptide chain
trace is once again highly similar to the main part of helix I and
remains so for the rest of the structure. Two minor exceptions
are the loop following the K helix and the C-terminal region,
which are both slightly reoriented and form part of the dome of
the active site. These reorganizations in the secondary ele-
ments and loops lining the active site cavity result in a slightly
increased volume for the CYP121 active site of 1337 Å com-
pared with 1115 Å for the substrate-bound CYP107A1.
Whereas in CYP121 the main part of the active site is more
compressed due to the closer packing of loops forming the dome
of the active site, a significant part of the cavity extends be-
tween helices F and G (Fig. 1), accounting for the increased
volume in CYP121. As has been observed for the majority of
P450 crystal structures (with the notable exceptions of Mtb
CYP51 and Bacillus megaterium P450 BM3) (14, 30), the active
TABLE II
Final refinement statistics for the CYP121 crystal structures
Data set Native Iodopyrazole
Space group P6522 P6522
Resolution (Å) 10–1.06 20–1.8
Rcryst
a (%) 13.2 20.5
Rfree












a Rcryst  Fo  Fc/Fo; Rfree is the same as Rcryst but was calcu-
lated using a separate validation set of reflections that was excluded
from the refinement process.
b r.m.s., root mean square.
FIG. 1. Overall fold of Mtb CYP121. The atomic structure of
CYP121 is composed mainly of  helices. The heme (in space fill) is
sandwiched between the two major domains of the structure: an 
helix-rich domain (dark gray) and the smaller  sheet-rich domain
(light gray). The large water-filled active site cavity of the enzyme is
shown as a transparent surface. An arrow indicates the possible site of
substrate entry between helices F and G.
FIG. 2. The heme binding motif in M. tuberculosis CYP121 and
other cytochromes P450. The heme-binding motif region for Mtb
CYP121 (10 amino acids either side of the cysteinate ligand to the heme
iron) is shown aligned versus those from prokaryotic and eukaryotic
P450s using the ClustalW program (EBI). Four amino acids are con-
served throughout, including the cysteine (Cys345 in CYP121), and are
highlighted in white against a black background. These identical resi-
dues are also indicated by an asterisk at the base of the alignment, and
other positions where the amino acid class is retained in each P450 are
indicated by dots. Highlighted in gray are those individual amino acids
present in 40% or more of the P450s at the respective positions. P450
enzymes are indicated by their formal classification “CYP” numbers (1)
and by their species of origin. Mtu, M. tuberculosis; Ser, S. erythraea;
Bsu, B. subtilis; Sso, S. solfataricus; Atu, Agrobacterium tumefaciens;
Bme, B. megaterium.
FIG. 3. Structural comparison of CYP121 with CYP107A1 (P450
EryF) from S. erythraea. Shown is a stereo view of the overlay of Mtb
CYP121 (dark gray) with S. erythraea CYP107A1 (light gray). Loops
and secondary elements lining the active site cavity are clearly more
divergent than the remainder of the structure.
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site is apparently inaccessible from the surface in this substrate-
free from of the enzyme. This obviously raises the question of how
the putative substrate reaches the active site. As has been pro-
posed for other P450s, we envisage the CYP121 structure as
oscillating between open and closed conformations whereby the
“breathing motions” of the protein, specifically movements of the
secondary elements and loops lining the active site, allow for
transient exposure of gaps allowing substrate access. It is espe-
cially interesting that the active site seems to protrude in be-
tween helices F and G, allowing small movements in the relative
positions of these helices to open an active site channel (Fig. 1).
Similar motions in helices F/G and the interconnecting loop re-
gion have been demonstrated to occur for the CYP119 monooxy-
genase from Sulfolobus solfataricus (31).
P450 Heme Binding in Atomic Detail—As in other P450
enzymes, a cysteine (Cys345) provides the proximal axial ligand
to the heme iron, with a well defined water molecule as the
distal axial ligand. The Fe-S distance is 2.30 Å, whereas the
Fe-O distance is 2.21 Å, both values being highly similar to
those in other P450 structures obtained.
An unusual aspect of the CYP121 structure is the fact that
the heme is clearly bound in one of two distinct conformations,
related by a 180° rotation through an axis of symmetry across
the Ch-Fe-CH atoms of the molecule. In short, the heme is
bound either in the “a” or “b” conformer, a phenomenon well
known for other heme proteins (e.g. cytochrome b5) (e.g. see Ref.
32). This mixture of conformers does not otherwise impact on
the overall fold of the enzyme. One of the conformers predom-
inates, and the relative occupancy is refined to a 70:30 mixture
of the species (Fig. 4a). In cytochrome b5, there is dynamic
exchange of the heme, such that the proportions of the a- and
b-type conformers can be perturbed considerably by tempera-
ture (e.g. see Ref. 33). The situation is extremely unlikely to be
the same in the cytochromes P450, where the heme is bound
deep in the protein (not superficially as in b5) and requires
protein denaturation to be released. Whereas insertion of heme
and modified hemes into P450 has been demonstrated, this was
achieved only very slowly by denaturation of the P450 and
refolding by gradual removal of denaturant after the addition
of the exogenous heme (e.g. see Ref. 34). The situation is highly
unlikely to occur in vivo, and we infer that the heme-binding
step in CYP121 (and other P450s) occurs at a relatively early
stage in the protein folding process, and the position of the
heme as bound commits the P450 to this conformation through-
out its lifetime in vivo.
One of the four pyrrole rings of the heme is distorted out-of-
plane by the close interaction with the side chain of Pro346. The
pyrrole is kinked toward the distal face by an angle of 30°
(Fig. 4b). Pro346 immediately follows the cysteinate heme li-
gand (Cys345), and this Cys-Pro motif is found in a number of
other cytochrome P450 enzymes, with several of the Mtb P450s
having this feature (Fig. 2). This structural perturbation to
heme planarity may therefore well be a feature common in
other P450 enzymes but previously unrecognized due to the
absence of the Cys-Pro motif in P450 structures solved to date.
This structural element could indeed be essential to the specific
electronic properties of the heme in these oxidases. Recently,
we have demonstrated in the P450 BM3 system that a phylo-
genetically conserved Phe residue (Phe393 located 7 amino ac-
ids before the cysteine ligand) that also stacks with both heme
plane and packs with the cysteinate ligand exerts a large effect
on the heme electronic properties (Fig. 2) (35). It is therefore
highly likely that this proline residue, being closer to both
heme and cysteinate ligand than even the phenylalanine
(Phe338 in CYP121), has a considerable impact on the heme
catalytic and thermodynamic properties.
The Oxygen Scission Site to Atomic Detail—The water ligand
to the heme in the resting state of the enzyme is hydrogen
bonding to Ser237. This residue replaces the more general thre-
onine residue found in cytochromes P450, which has been im-
plicated in oxygen binding and/or proton delivery (36, 37). In
turn, Ser237 hydrogen-bonds to the carbonyl backbone of Ala233
and to the side chain of Arg386 (Figs. 4b and 5). Whereas a
distinctive deviation of conventional -helix hydrogen bonding
patterns in the region of the water ligand-contacting residues
can be seen in all P450s of known structure, with the exception
of CYP2C5 (9), the I helix in CYP121 is devoid of any signifi-
cant alteration of hydrogen bonding patterns and resembles
the eukaryotic CYP2C5 in this region. The presence of the
bulky and positively charged residue Arg386 immediately adja-
cent to the oxygen scission site is unique to CYP121 and makes
it one of the key residues in this enzyme (Fig. 4b). The side
chain of Arg386 is wedged in between Ile236 and Phe280,
whereas hydrogen bonding to Ser237, Gln385, and two water
molecules in the active site cavity. The close proximity of the
arginine and serine residues may define a binding site for a
negatively charged functional group, possibly a carboxylate, as
observed previously for e.g. P450 BM3 (CYP102A1) with its
fatty acid substrates (38, 39).
In the last stages of refinement, additional density became
FIG. 4. A, different heme conformations in CYP121. The main conformation of the heme B group of CYP121 is shown, surrounded with 1.5 (blue)
and 4 (purple)  contoured 2FoFc electron density. The additional FoFc density (contoured at 3  in green) and the lack of strong 2FoFc density
of the vinyl atoms of the main conformation clearly indicate a second conformer. The two different conformers are related by the indicated 180°
rotation about the heme plane. b, stereo view of the active site of CYP121. Residues surrounding the heme are shown in addition to the putative
oxygen ligand. The corresponding 2FoFc electron density is contoured at 1.5  in blue. The heme is notably kinked due to the close interaction with
Pro346. The FoFc density is contoured at 3  in green and reveals a second atom close to the position of the sixth water ligand.
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apparent immediately adjacent to the heme water ligand. The
shape of this density is nearly spherical, and the center is
located 1.2 Å from the sixth ligand (Fig. 4b). Only two models
seem to fit this density equally well: either the sixth ligand
occupies two distinct and mutually exclusive conformations, or
a diatomic species with 1.2-Å bond length (e.g. dioxygen) is
bound to a proportion of the heme groups in the crystal, effec-
tively superposing the densities of water ligation and dioxygen
ligation. The presence of hydrogen peroxide can be excluded on
the basis that the bond length of the observed species is signif-
icantly shorter than that of hydrogen peroxide (1.5 Å). The
immediate environment of the additional density does not,
however, correlate with the first model (i.e. two distinct water
conformations), since there are no significantly stabilizing
structural elements present to explain the fact that the ligating
water molecule would preferentially bind outside, but close to,
the ligation sphere of the iron. Therefore, we favor the second
model (i.e. bound dioxygen), with an angle of nearly 120° be-
tween dioxygen and heme plane highly similar to other dioxy-
gen-heme structures (e.g. see Ref. 40). However, it is unprece-
dented that dioxygen binds to ferric heme, and the possibility
exists that the crystal might have partially reduced in the
intense beam. However, during data collection, several parts of
the crystal were exposed each for less than 10 s, minimizing the
chance of significant reduction due to repetitively exposing
fresh, fully oxidized parts of the crystal. Additionally, several
data collections at medium resolution involving significantly
longer exposures and higher irradiation doses in similar con-
ditions did not reveal any additional density. Second, the pu-
tative bond length for the dioxygen-ferric ion is 2.2 Å, which is
highly similar to the water-ferric ion distances but in signifi-
cant deviation for dioxygen-ferrous ion distances of 1.8 Å.
Therefore, we conclude that P450 enzymes might weakly bind
dioxygen in the ferric form, a consequence of the electron rich
character conferred upon the heme by the cysteinate ligation.
The putative dioxygen species forms an ideal model for an-
alyzing the initial steps of the catalytic cycle, during which
both electrons and protons need to be consecutively passed onto
the ligand to break the dioxygen bond and create the highly
reactive oxidizing intermediate. Upon initial reduction of the
heme, the dioxygen molecule can either accept a proton from
proximal water molecules or from Ser237. However, we assume
that the active site will be devoid of water molecules in the
vicinity of the heme plane when complexed with substrate.
Ser237, in turn, can easily receive a proton from Arg386. This
residue contacts a water molecule buried in the interior of the
protein. At this point, there are several other residues contact-
ing this water molecule that could provide a proton. Most
notable is Ser279, which occupies two distinct conformations in
the CYP121 structure. Each of these conformations is in con-
tact with a different series of residues and buried water mole-
cules that eventually lead up to the surface of the molecule.
Thus, it appears plausible that there may be a bifurcated
proton delivery pathway from the P450s surface, with path-
ways converging at Ser279. This would have the potential to
transport one proton at a time through each individual path
(Fig. 6).
Structure of the Substrate Binding Site—The active site cav-
ity of 1350 Å3 is filled with water molecules and is remarkably
rigid. Whereas a significant proportion of both surface-exposed
and interior residues exhibit multiple conformations, all of the
residues involved in lining the active site adopt a single con-
formation. The dome of the active site chamber is 12 Å above
the heme plane, being most open above pyrrole ring D (main
conformation). The heme is 62 Å2 solvent-exposed with access
to pyrroles B and C limited by residues from the I helix. The
majority of residues lining the active site are hydrophobic with
the notable exceptions of Arg386 and Gln385. Whereas several
antifungal agents bind tightly to CYP121 in solution (20), we
have been unable to date to obtain crystallographic complexes
with these compounds by either soaking native crystals or
conducting co-crystallization trials. This is highly likely due to
the extreme insolubility of the polycyclic azoles in the ammo-
nium sulfate mother liquor but could also be due to restricted
access of the azoles to the heme due to obstruction by Arg386.
The single azole compound that was proven to bind into the
active site cavity by soaking the crystals was iodopyrazole. This
clearly demonstrates the fact that, even in the tight crystal
FIG. 5. Hydrogen bonding pattern in the CYP121 I helix. Resi-
dues of the CYP121 I helix close to the heme group are shown in gray
ball and stick mode. All bacterial cytochromes P450 show a severe
disruption of the hydrogen bonding pattern between Ala233 and Ser237
(CYP121 numbering). Remarkably, this distortion is not seen in
CYP121 in the vicinity of the relevant amino acid (Ser237), similar to the
mammalian CYP2C5 structure (9).
FIG. 6. Putative proton relays in CYP121. Shown is a view of two
putative proton pathways leading from the solvent into the active site.
Both pathways are mainly made by buried water molecules in addition
to a single amino acid (Thr244 and Glu310, respectively) in the two
pathways. These pathways merge at Ser279 that occupies two distinct
conformations, each contacting a water molecule that is hydrogen-
bonded to Arg386. The latter residue is proposed to donate protons either
directly or via Ser237 (not shown) to the oxygen intermediates.
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packing, breathing motions must allow transient access from the
outside into the otherwise inaccessible active site cavity. Surpris-
ingly, the pyrazole compound does not ligate to the heme iron but
binds instead in the small channel region between helices F and
G. The pyrazole plane stacks at 4 Å with Trp182 on one side and
Phe168 on the other side (Fig. 7, a and b). The bulky iodide atom
points toward the active site cavity and is buried between the
hydrophobic side chains of Phe168, Thr229, and Ala233. A similar
unexpected observation was made upon complexation with
4-phenylimidazole. In this case, the compound bound to the sur-
face of the protein instead of acting as the sixth heme ligand. In
spectral titrations, 4-phenyl imidazole was shown to bind to the
heme iron, giving a typical (and complete) shift of the Soret
maximum to 423 nm. This clearly demonstrates that CYP121
can adopt conformations in solution distinct from that observed
in the crystal and that these solution conformations are compat-
ible with ligand binding to the iron.
CONCLUSIONS
CYP121 is similar in overall fold to other structurally char-
acterized P450s. It contains unique structural elements in-
volved in lining the active site. The heme binding and oxygen
scission sites are particularly interesting, since these reveal
several new features that could be general to P450s. First, the
heme cofactor is bound in two distinct, mutually exclusive
conformations. Furthermore, it is contorted due to close inter-
action with the Cys345-Pro346 motif, a common structural ele-
ment in Mtb P450s and present also in other prokaryotic and
eukaryotic forms. A series of hydrogen-bonded amino acid and
water molecules define two potential proton delivery pathways,
and these apparently converge at Ser278, which has distinct
conformations in the CYP121 structure. Most interestingly, the
oxygen scission site is markedly different from other bacterial
P450s, and, while resembling the eukaryotic CYP2C5 struc-
ture, it contains a unique arginine residue (Arg386). The atomic
resolution obtained has allowed visualization of a species (prob-
ably dioxygen) weakly bound to the ferric heme iron.
Future studies on CYP121 will involve establishing its sub-
strate selectivity through screening for activity against myco-
bacterial lipid extracts (and possibly infected tissue samples)
and use of rational mutagenesis to define roles of key amino
acids identified from this structural study in determining the
biophysical and catalytic properties of the P450. A further
priority is the solution of an azole-ligated CYP121 structure,
since this may provide critical information required to facilitate
de novo design of novel and more highly specific azole drugs
that are potent anti-mycobacterials but that lack the cross-
reactivity with human isoforms. Through such an approach,
anti-P450 drugs may prove useful new agents in the war
against multidrug-resistant strains of M. tuberculosis, which
the World Health Organization describes as having the poten-
tial to cause a “global catastrophe.”
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